Chalcogen Bonded Directly To Ring Carbon Of The Hetero Ring Patents (Class 514/455)
-
Patent number: 7329687Abstract: Compounds useful as chemotherapeutic, chemopreventive, and antiangiogenic agents are provided. The compounds are flavanoids, including flavanones, flavanols, and chalcones. The compounds have the structure of formula (I) wherein R1 through R3 and R5 through R11 are defined herein, and ?, ?, and ? are optional bonds, providing that when ? is absent, ? is present, and when ? is absent, ? is present. When ? is present, preferred R4 moieties are selected from O, S, NH and CH2, and when ? is absent, preferred R4 groups are selected from OH, SH, NH2 and CH3. When ? is present, the preferred R5 substituent is O, while when ? is absent, the preferred R5 substituent is OH. Pharmaceutical compositions are provided as well, as are methods of synthesis and use.Type: GrantFiled: April 18, 2003Date of Patent: February 12, 2008Assignee: SRI InternationalInventors: Nurulain Zaveri, Wan-Ru Chao
-
Patent number: 7326734Abstract: Compositions of matter and methods wherein chalcone and flavone derivatives are administered to human or veterinary patients for the treatment of bladder or urinary tract cancer. Compounds of the invention include 2?-hydroxy-4,4?,6?-trimethoxychalcone (Flavokawain A).Type: GrantFiled: April 1, 2004Date of Patent: February 5, 2008Assignee: The Regents of the University of CaliforniaInventors: Xiolin Zi, Anne R. Simoneau
-
Patent number: 7317038Abstract: To provide a semaphorin inhibitor; a peripheral or central nerve regeneration promoter which contains said semaphorin inhibitor as an active ingredient; and a preventive or remedy for a neuropathic disease and a neurodegenerative disease containing said nerve regeneration promoter, or the like. A low-molecular weight compound, which acts at a concentration of 10 ?g/ml or below to inhibit the growth cone collapse activity of semaphorin such as semaphorin 3A, semaphorin 6C or the like and/or the nerve outgrowth inhibitory activity of semaphorin in a collagen gel and which does not substantially affect cell proliferation, is obtained from the culture of strain SPF-3059 belonging to the genus Penicillium. The low-molecular weight compound with the semaphorin inhibitory activity thus obtained exhibits the in vivo nerve-regeneration promoting action.Type: GrantFiled: August 24, 2006Date of Patent: January 8, 2008Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Toru Kimura, Kaoru Kikuchi, Kazuo Kumagai, Nobuo Hosotani, Akiyoshi Kishino
-
Patent number: 7253207Abstract: Novel quinones are provided, as well as compositions comprising these novel quinones. Methods of using the novel quinones in treatment of various indications including cancer are also provided.Type: GrantFiled: August 2, 2004Date of Patent: August 7, 2007Assignee: Cellgate, Inc.Inventors: Andrei V. Blokhin, Benjamin Frydman, Laurence J. Marton, Karen M. Neder, Jerry Shunneng Sun
-
Patent number: 7244761Abstract: To provide a semaphorin inhibitor; a peripheral or central nerve regeneration promoter which contains said semaphorin inhibitor as an active ingredient; and a preventive or remedy for a neuropathic disease and a neurodegenerative disease containing said nerve regeneration promoter, or the like. A low-molecular weight compound, which acts at a concentration of 10 ?g/ml or below to inhibit the growth cone collapse activity of semaphorin such as semaphorin 3A, semaphorin 6C or the like and/or the nerve outgrowth inhibitory activity of semaphorin in a collagen gel and which does not substantially affect cell proliferation, is obtained from the culture of strain SPF-3059 belonging to the genus Penicillium. The low-molecular weight compound with the semaphorin inhibitory activity thus obtained exhibits the in vivo nerve-regeneration promoting action.Type: GrantFiled: July 27, 2001Date of Patent: July 17, 2007Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Toru Kimura, Kaoru Kikuchi, Kazuo Kumagai, Nobuo Hosotani, Akiyoshi Kishino
-
Patent number: 7244760Abstract: Psorospermin is a cytotoxic dihydroflranoxanthone that has found to exhibit significant activity against various tumor cell lines. Unfortunately, psorospermin is no longer readily available from its natural plant source. The present invention is directed to a method for preparing psorospermin and psorospermin analogs. Methods are also disclosed for utilizing psorospermin analogs to inhibit cellular proliferation.Type: GrantFiled: May 20, 2002Date of Patent: July 17, 2007Assignees: Board of Regents, The University of Texas System, Cylene Pharmaceuticals, Inc.Inventors: Laurence Hurley, Ingrid Fellows, Michael Kenric Schwaebe, Jeffrey Paul Whitten
-
Patent number: 7238725Abstract: The present invention relates to novel tricyclic compounds useful for the treatment of inflammatory conditions, diseases of the central nervous and insulin resistant diabetes.Type: GrantFiled: October 8, 2003Date of Patent: July 3, 2007Assignee: Glenmark Pharmaceuticals Ltd.Inventors: Gopalan Balasubramanian, Laxmikant A. Gharat, Aftab D. Lakdawala, Raghu R. Anupindi
-
Patent number: 7230027Abstract: Compositions, methods, etc. for addressing the first-pass effect.Type: GrantFiled: March 16, 2005Date of Patent: June 12, 2007Assignee: Bioavailability Systems, L.L.C.Inventor: James W. Harris
-
Patent number: 7223789Abstract: The present invention relates to novel heterocyclic compounds, their analogs, their tautomers, their regioisomers, their stereoisomers, their enantiomers, their diastereomers, their polymorphs, their pharmaceutically acceptable salts, their appropriate N-oxides, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. The present invention more particularly relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the Formula (1), their analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxide, pharmaceutically acceptable solvates and the pharmaceutical compositions containing them.Type: GrantFiled: April 9, 2004Date of Patent: May 29, 2007Assignee: Glenmark Pharmaceuticals S.A.Inventors: Balasubramanian Gopalan, Laxmikant Atmaram Gharat, Aftab Dawoodbhai Lakdawala, Usha Karaunakaran
-
Patent number: 7208518Abstract: The present invention relates to novel compounds of the formula (I) including all stereoisomers and tautomers thereof, to the pharmaceutically acceptable salts and solvates thereof, to the processes and reactive intermediates for their preparation and to their use in the prophylaxis and treatment of asthma and other inflammatory diseases and/or conditions in humans.Type: GrantFiled: January 23, 2006Date of Patent: April 24, 2007Assignee: GlaxoSmithKline Istrazivacki Centar Zagreb D.O.O.Inventors: Mladen Mercep, Milan Mesic, Boska Hrvacic, Ivaylo Jivkov Elenkov, Ivica Malnar, Stribor Markovic, Lidija Simicic, Andreja Cempuh Klonkay, Anita Filipovic
-
Patent number: 7208594Abstract: Isoflavone concentrates are described, which contain at least about ten to about twenty weight parts of polysorbate to one weight part of isoflavone containing a genistein, and/or daidcein, and/or glycitein. Further, a method for the production of an isoflavone concentrate is described.Type: GrantFiled: June 29, 2002Date of Patent: April 24, 2007Assignee: Aquanova AGInventor: Dariush Behnam
-
Patent number: 7202272Abstract: A compound is described. In particular, a non-steroidal sulphamate compound is described. The compound is suitable for use as an inhibitor of oestrone sulphatase. The compound is of general Formula (A), wherein R1–R6 are independently selected from H, halo, hydroxy, sulphamate, alkyl and substituted variants or salts thereof; but wherein at least one of R1–R6 is a sulphamate group; and wherein X is any one of S, NH, a substituted N, CH2, or a substituted C.Type: GrantFiled: November 17, 2004Date of Patent: April 10, 2007Assignee: Sterix, Ltd.Inventors: Michael John Reed, Barry Victor Lloyd Potter
-
Patent number: 7183313Abstract: Novel tricyclic cannabinoid compounds are presented. Some of these compounds exhibit fluorescence properties. The fluorescent cannabinoid compounds are typically endogenously fluorescent. Some of these compounds, when administered in a therapeutically effective amount to an individual or animal, result in a sufficiently high level of that compound in the individual or animal to cause a physiological response. The physiological response useful to treat a number of physiological conditions.Type: GrantFiled: August 25, 2003Date of Patent: February 27, 2007Assignee: University of ConnecticutInventors: Alexandros Makriyannis, Dai Lu, Xin-Zhong Lai
-
Patent number: 7182964Abstract: A nutraceutical composition containing xanthones for oral ingestion is disclosed. The composition is a rapidly dissolving film comprising water soluble polymers and xanthones. The xanthones are, preferably, derived from natural plant sources, especially from fruit of Garcinia mangostana L. plant.Type: GrantFiled: November 12, 2004Date of Patent: February 27, 2007Assignee: DBC, LLCInventors: Roman Kupper, Marlene Smothers
-
Patent number: 7115655Abstract: The present invention relates to compounds of the following formula (I) or pharmaceutically acceptable salts thereof. The present invention also relates to use for a cognitive-enhancing agent of compounds of the following formula (I) or pharmaceutically acceptable salts thereof and to a process for preparing the same. Further, the present invention relates to use for a congnitive-enhancing agent of decursin of the following formula (II) or pharmaceutically acceptable salts thereof. In addition, the present invention relates to extracts of Angelica gigantis Radix comprising decursin of the following formula (II), having cognitive-enhancing effects.Type: GrantFiled: April 9, 2002Date of Patent: October 3, 2006Assignee: Elcom Biotechnology, Co. Ltd.Inventors: Jeong-Seon Yoon, Ji-Young Lee, Young-Choong Kim, Ki-Yong Lee, Sang-Hyun Sung, Hak-Joong Kim, So-Young Kang
-
Patent number: 7098188Abstract: The invention relates to novel pharmaceutically acceptable salts of anticonvulsant derivatives, processes for preparation of and pharmaceutical compositions containing said salts, useful in the treatment of epilepsy.Type: GrantFiled: July 3, 2002Date of Patent: August 29, 2006Assignee: Ortho-McNeil Pharmaceutical., Inc.Inventors: Ahmed Abdel-Magid, Cynthia Maryanoff
-
Patent number: 7094378Abstract: Methods and apparatuses for treating fluids to inactivate microorganisms which may be present therein, said fluid containing one or more components selected from the group consisting of protein, blood and blood constituents are provided. The methods comprise adjusting the percentage of plasma in said fluid to a desired value; mixing an inactivation-effective, substantially non-toxic amount of an endogenous photosensitizer or endogenously-based derivative photosensitizer to said fluid; exposing said fluid to photoradiation of sufficient wavelength and energy to activate the photosensitizer, whereby said microorganisms are inactivated.Type: GrantFiled: June 15, 2000Date of Patent: August 22, 2006Assignee: Gambro, Inc.Inventors: Raymond Paul Goodrich, Jr., Dennis Hlavinka
-
Patent number: 7087640Abstract: A substance with sedative effect comprises a therapeutically effective amount of a gamma-pyrone such as comenic acid, meconic acid, chelidonic acid, and alike in a pharmaceutically acceptable carrier. When administered at a daily dosage of between 5 and 200 mg of active ingredient per kilogram of a body weight of a patient, the substance can be used to treat various neurotic disorders such as insomnia, anxiety, neurosis, depression as well as withdrawal symptoms for drug addiction patients, especially for patients addicted to opioid-based drugs. The substance can be delivered in a number of ways of systemic administration of a pharmaceutical agent including oral, parenteral, transdermal, and transmucosal administration. For drug addicted patients, the preferred method of administration involves a subcutaneous implant providing a continuous release of an active ingredient at an effective daily rate over the entire treatment period ranging from 5 to 30 days, and preferably from 13 to 20 days.Type: GrantFiled: March 14, 2003Date of Patent: August 8, 2006Assignee: Technology Commercialization CorpInventors: Boris Vladimirovich Krylov, Boris Fedorovich Shchegolev
-
Patent number: 7074824Abstract: Beta-lapachone, which is poorly soluble in most pharmaceutically acceptable solvents, has demonstrated significant antineoplastic activity against human cancer lines. The present invention overcomes this significant limitation by teaching novel pharmaceutical compositions comprising a therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and a pharmaceutically acceptable solubilizing carrier molecule, which may be at water-solubilizing carrier molecule such as hydroxypropyl-?-cyclodextrin, or an oil-based solubilizing carrier molecule, for enhancing the solubility of Beta-lapachone in aqueous solution. The therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, may be complexed with the pharmaceutically acceptable solubilizing carrier molecule in aqueous solution. The novel pharmaceutical compositions may be administered with a second anticancer agent or in combination with radiation therapy.Type: GrantFiled: July 31, 2002Date of Patent: July 11, 2006Assignee: Arqule, Inc.Inventors: Zhiwei Jiang, Dasharatha G. Reddy
-
Patent number: 7041650Abstract: The invention relates to novel pharmaceutically acceptable salts of anticonvulsant derivatives, processes for preparation of and pharmaceutical compositions containing said salts, useful in the treatment of epilepsy.Type: GrantFiled: January 3, 2003Date of Patent: May 9, 2006Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Ahmed Abdel-Magid, Cynthia Maryanoff
-
Patent number: 7019024Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 9, 2001Date of Patent: March 28, 2006Assignee: Allelix Neuroscience Inc.Inventors: Vassil Iliya Ognyanov, Laurence A. Borden, Stanley Charles Bell, Jing Zhang
-
Patent number: 7015194Abstract: The present invention relates to the use of factor VIIa and TFPI inhibitor in the treatment or prophylaxis of bleeding episodes or coagulative treatment.Type: GrantFiled: October 16, 2002Date of Patent: March 21, 2006Assignee: Novo Nordisk A/SInventor: Marianne Kjalke
-
Patent number: 6995187Abstract: Novel polycyclic cannabinoid analogs are presented which have preferentially high affinities for the cannabinoid CB2 receptor sites. The improved receptor affinity makes these analogs therapeutically useful as medications in individuals and animals for treatment of pain, glaucoma, epilepsy, nausea associated with chemotherapy.Type: GrantFiled: October 18, 2000Date of Patent: February 7, 2006Assignee: University of ConnecticutInventors: Alexandros Makriyannis, Atmaram Khanolkar
-
Patent number: 6962931Abstract: CETP Inhibitors have improved solubility and bioavailability in a lipophilic vehicle comprising a digestible oil, a lipophilic solvent, or a surfactant. Preferred such compositions are self-emulsifying or self-microemulsifying, and comprise 1. a CETP inhibitor; 2. a cosolvent; 3. a surfactant having an HLB of 1 to 8; 4. a surfactant having an HLB of over 8 to 20; and 5. optionally, a digestible oil.Type: GrantFiled: June 19, 2002Date of Patent: November 8, 2005Assignee: Pfizer Inc.Inventors: Michael J. Gumkowski, Lombardo Franco, Sharad B. Murdande, Michael E. Perlman
-
Patent number: 6962944Abstract: Beta-lapachone, which is poorly soluble in most pharmaceutically acceptable solvents, has demonstrated significant antineoplastic activity against human cancer lines. The present invention overcomes this significant limitation by teaching novel pharmaceutical compositions comprising a therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and a pharmaceutically acceptable solubilizing carrier molecule, which may be at water-solubilizing carrier molecule such as hydroxypropyl-?-cyclodextrin, or an oil-based solubilizing carrier molecule, for enhancing the solubility of Beta-lapachone in aqueous solution. The therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, may be complexed with the pharmaceutically acceptable solubilizing carrier molecule in aqueous solution. The novel pharmaceutical compositions may be administered with a second anticancer agent or in combination with radiation therapy.Type: GrantFiled: October 10, 2001Date of Patent: November 8, 2005Assignee: Arqule, Inc.Inventors: Zhiwei Jiang, Dasharatha G. Reddy
-
Patent number: 6960300Abstract: Aqueous solutions of diterpenes such as Forskolin, its congeners, analogs and derivatives, up to approximately 6% concentration, are prepared using suitably substituted cyclodextrin as a solubilizing agents. In the absence of cyclodextrin, some diterpenes such as Forskolin are soluble in water only to concentrations of about 0.001%. Such aqueous solutions find applications in topical and systemic use, as pharmaceutical, cosmeceutical, nutraceutical preparations containing diterpenes such as Forskolin and congeners.Type: GrantFiled: September 8, 2003Date of Patent: November 1, 2005Assignee: Sami Labs LimitedInventors: Muhammed Majeed, Arvind Kumar, Kalyanam Nagabhushanam, Subbalakshmi Prakash
-
Patent number: 6939977Abstract: Disclosed are novel compounds represented by the following structural formula: R-X-Y; and physiologically acceptable salts thereof. R is a tricyclic core of a cannabinoid or substituted cannabinoid. X is a covalent bond, —CH2— or —CHR1—, wherein R1 a C1 to C3 substituted or unsubstituted alkyl group. Y is a heterocyclic ring, a substituted heterocyclic ring, a carbocyclic ring, a substituted carbocyclic ring, a fused bicyclic ring system, a substituted fused bicyclic ring system, a bridged bicyclic ring system, a substituted bridged bicyclic ring system, a bridged tricyclic ring system or a substituted bridged tricyclic ring system. Also disclosed is a method of stimulating a CB1 and/or CB2 receptor in a subject. The method comprises administering to the subject a therapeutically effective amount of R-X-Y.Type: GrantFiled: December 4, 2002Date of Patent: September 6, 2005Assignee: The University of ConnecticutInventors: Alexandros Makriyannis, Dai Lu, Atmaram Khanolkar
-
Patent number: 6936719Abstract: Compounds of formula (I) are useful as inhibitors of trypsin like serine protease enzymes such as thrombin, factor VIIa, factor Xa, TF/FVIIa, and trypsin. These compounds could be useful to treat and/or prevent clotting disorders, and as anticoagulating agents.Type: GrantFiled: December 18, 2003Date of Patent: August 30, 2005Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Yarlagadda S. Babu, R. Scott Rowland, Pooran Chand, Pravin L. Kotian, Yahya El-Kattan, Shri Niwas
-
Patent number: 6921775Abstract: Methods are disclosed for modulating brain damage mediated by non-NMDA ionotropic glutamate receptor antagonists, as topiramate, in conditions such as periventricular leukomalacia, cerebral palsy, mental retardation and neonatal stroke.Type: GrantFiled: August 5, 2002Date of Patent: July 26, 2005Assignee: Children's Medical Center CorporationInventors: Frances E. Jensen, Joseph Volpe, Paul Rosenberg, Pamela L. Follett
-
Patent number: 6890951Abstract: The present invention relates to the use of a composition that increases central nervous system GABA levels in a mammal, for the treatment of addiction to drugs of abuse and modification of behavior associated with addiction to drugs of abuse in said mammal.Type: GrantFiled: August 20, 2001Date of Patent: May 10, 2005Assignee: Brookhaven Science Associates LLCInventors: Stephen L. Dewey, Jonathan D. Brodie, Charles R. Ashby, Jr.
-
Patent number: 6890950Abstract: In part, the present invention is directed to a system comprising a lapachone or a prodrug thereof and a polymer, such as a biocompatible and optionally biodegradable polymer, methods for treatment using the subject polymer compositions, and methods of making and using the same. In another part, the present invention includes inclusion complexes of a lapachone or a prodrug thereof and a cyclodextrin, preferably a ?-cyclodextrin, such as hydroxypropyl ?-cyclodextrin, e.g., to improve the solubility of the lapachone or prodrug thereof.Type: GrantFiled: April 23, 2003Date of Patent: May 10, 2005Assignee: Case Western Reserve UniversityInventors: David Boothman, Jinming Gao, Norased Nasongkla, John Pink
-
Patent number: 6887862Abstract: A method in which photodynamic therapy is employed to inhibit, stabilize or reduce occlusions within the cardiovascular system by utilizing light within the spectral region of approximately 390 to approximately 610 nm.Type: GrantFiled: May 31, 2001Date of Patent: May 3, 2005Assignee: Miravant Systems, Inc.Inventor: Steven J. Rychnovsky
-
Patent number: 6887895Abstract: The invention relates to pseudolaric acid-B derivatives of general formula (I), wherein (a) R1 is cyano, heterocyclyl, COXR? or CON(R?)2, wherein X is O or NH, R? is H, cycloalkyl, alkyl, heterocyclic alkyl or arylalkyl, each R? is independently alkyl, cycloalkyl or heterocyclicalkyl; (b) R2 is H, alkylacyl, arylalkylacyl, arylacyl or heterocyclylacyl; (c) R3 is COXY, amino or halogen, wherein X is O or NH, Y is H, NH2, hydroxy, alkyl, cycloalkyl, heterocyclicalkyl, hetroatom-substituted alkyl, tertiary amino-substituted ammonioalkyl, aryl, arylalkyl or polyhydroxyalkyl. The invention also relates to processes for preparing such derivatives and antitumor or antifungal pharmaceutical compositions containing the same.Type: GrantFiled: August 14, 2002Date of Patent: May 3, 2005Assignee: Shanghai Institute of Materia Medica Chinese Academy of ScienceInventors: Jianmin Yue, Shengping Yang, Jian Ding, Dong Xiao, Shengtao Yuan
-
Patent number: 6878718Abstract: Phenylalanine enamide derivatives of formula (1) are described: wherein R1 is a group Ar1L2Ar2Alk- in which: Ar1 is an optionally substituted aromatic or heteroaromatic group; L2 is a covalent bond or a linker atom or group; Ar2 is an optionally substituted arylene or heteroarylene group; and Alk is a chain —CH2—CH(R)—, —CH?C(R)— or ?in which R is a carboxylic acid (—CO2H) or a derivative or biostere thereof; X is an —O— or —S— atom or —N(R2)— group in which: Rx, Ry and Rz which may be the same or different is each a hydrogen atom or an optional substituent; or Rz is an atom or group as previously defined and Rx and Ry are joined together to form an optionally substituted spiro linked cycloaliphatic or heterocycloaliphatic group; and the salts, solvates, hydrates and N-oxides thereof.Type: GrantFiled: February 22, 2002Date of Patent: April 12, 2005Assignee: Celltech R&D LimitedInventors: Stephen Brand, Stuart Bailey, Julien A. Brown, James A. Johnson, John R. Porter, John C. Head
-
Patent number: 6875745Abstract: We have discovered that the administration of a G1 and/or S phase drug such as ?-lapachone in combination with a G2/M drug such as a taxane derivative such as paclitaxel resulted in a greater than additive (i.e., synergistic) reduction in the number of tumors (and tumor volume) as compared with the administration of these agents alone. In addition, no signs of toxicity or weight loss were observed. The present invention relates to a method for treating a mammalian tumor using combinations such as a taxane derivative, preferably paclitaxel, and a ?-lapachone, or a derivative or analog thereof.Type: GrantFiled: October 9, 2003Date of Patent: April 5, 2005Assignee: Dana Farber Cancer Institute, Inc.Inventors: Arthur B. Pardee, Chiang J. Li, Youzhi Li
-
Patent number: 6825226Abstract: The invention relates to the discovery that specific adamantyl or adamantyl group derivatives containing retinoid-related compounds induce apoptosis of cancer cells and therefore may be used for the treatment of cancer, including advanced cancer. Also, the present invention relates to novel adamantyl or adamantyl group derivatives containing retinoid compounds and their usage for treatment and/or prevention of cancer, keratinization disorders, dermatological conditions, and other therapies More specifically, it has been shown that such adamantyl compounds, e.g., 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoicacid, 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid, and 6-[3-(1-adamantyl)-4,5-methylenedioxyphenyl]-2-naphthoic acid, can be used to treat or prevent cervical cancers and precancers such as cervical dysplasias, including high grade and low grade dysplasias.Type: GrantFiled: June 24, 2002Date of Patent: November 30, 2004Assignee: Galderma Research & Development, S.N.C.Inventors: Magnus Pfahl, Xian-Ping Lu, Darryl Rideout, Hongyue Zhang
-
Publication number: 20040229899Abstract: The present invention relates to compounds of formula (I) 1Type: ApplicationFiled: January 6, 2004Publication date: November 18, 2004Inventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
-
Publication number: 20040204480Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.Type: ApplicationFiled: March 2, 2004Publication date: October 14, 2004Applicant: Cancer Research Technology LimitedInventors: William R. Wilson, Bronwyn G. Siim
-
Patent number: 6797729Abstract: Compositions comprising glutamine in combination with other ingredients such as N-acetyl-cysteine are disclosed. Such compositions can be administered to treat patients with certain conditions of the body.Type: GrantFiled: June 27, 1997Date of Patent: September 28, 2004Assignee: Baxter International Inc.Inventors: Theresa A. Byrne, Joanne A. Somerville
-
Patent number: 6790463Abstract: The use of a pharmaceutical formulation in treating coronary arteriosclerosis and a two-component pharmaceutical formulation. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimithyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone.Type: GrantFiled: March 30, 2001Date of Patent: September 14, 2004Inventors: Robert F. Hofmann, Robert H. Carpenter
-
Patent number: 6784204Abstract: This disclosure describes new antibiotic Cytosporacin having the structure: The invention relates to a new antibiotic designated Cytosporacin, to its production by fermentation, to methods for its recovery and concentration from the crude solutions, and to process for its purification. The invention includes within its scope the agent in dilute form, as a crude concentrate, and in pure form. The invention also relates to the use of the compound according to the invention in antimicrobial compositions and as antiseptics or disinfectants.Type: GrantFiled: October 14, 2003Date of Patent: August 31, 2004Assignee: Wyeth Holdings Corporation, Five Giralda FarmsInventors: Haiyin He, Jeffrey Edwin Janso
-
Publication number: 20040162337Abstract: Chemical compounds of the general formula 1Type: ApplicationFiled: January 30, 2003Publication date: August 19, 2004Inventors: Wang Fun Fong, Yiu Cheong Jimmy Wu
-
Patent number: 6774142Abstract: 3-Deoxyflavonoid compounds and methods for inhibiting T-cell activity and treating diseases and disorders (e.g., autoimmune disorders, inflammatory disorders, diabetes, ALS, MS, rheumatoid arthritis, etc.). In some cases the efficacy and/or duration of action of luteolin and/or other 3-dioxyflavinoid compounds may be increased by administering such compounds along with Rutin, a Rutin congener and/or a Rutin derivative. Also, in some cases, first pass metabolism of luteolin or other 3-deoxyflavinoids may be avoided by administering such compounds by parenteral routes (e.g., sublingual, buccal, intranasal, injection, etc.).Type: GrantFiled: September 6, 2002Date of Patent: August 10, 2004Inventors: Thomas P. Lahey, Vithal J. Rajadhyasksha
-
Patent number: 6770671Abstract: Disclosed are a novel compound represented by the following chemical formula (1), useful for the prophylaxis and treatment of angiogenic diseases, its production, and a novel microorganism producing the same. Aspergillus sp. Y80118 isolated from soil was found to produce 7,8-dihydro-1,7-dihydroxy-3-hydroxymethyl-xanthenone-8-carboxylic acid methylester which inhibits VEGF-induced proliferation of HUVEC, angiogenesis in CAM assay, and tumor growth. The novel compound can be effectively used for the medical treatment of anigiogenic diseases, including cancers, rheumatoid arthritis, and diabetic retinopathy.Type: GrantFiled: September 4, 2002Date of Patent: August 3, 2004Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Jung Joon Lee, Jeong-Hyung Lee, Hang Sub Kim, Young-Soo Hong, Yun Joo Park
-
Publication number: 20040110784Abstract: The present invention provides a therapeutic agent for bladder irritative symptoms associated with benign prostatic hyperplasia comprising, as an active ingredient, a tricyclic compound represented by formula (I): 1Type: ApplicationFiled: September 22, 2003Publication date: June 10, 2004Inventors: Tsuyoshi Yamagata, Kaoru Atsuki, Tetsuji Ohno, Shiro Sirakura, Akira Karasawa
-
Patent number: 6740676Abstract: Compounds of Formula 1: wherein the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.Type: GrantFiled: March 19, 2002Date of Patent: May 25, 2004Assignee: Allergan, Inc.Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok-Yin Tsang, Yang-Dar Yuan, Roshantha S. Chandraratna
-
Patent number: 6737439Abstract: A composition and method of cancer treatment is disclosed. The composition and method utilized the extract of B. papyrifera, or compounds included therein having aromatase inhibition properties, as active cancer chemopreventative and treating agents in mammals, including humans.Type: GrantFiled: July 25, 2002Date of Patent: May 18, 2004Assignee: The Board of Trustees of the University of IllinoisInventors: Alan Douglas Kinghorn, John M. Pezzuto, Dongho Lee, Krishna P. L. Bhat
-
Publication number: 20040087611Abstract: Methods and composition are provided for treating cancer, the methods including the step a administering, either sequentially or simultaneously, (i) a compound of the xanthenone acetic acid group of compounds, and (ii) at least one compound selected from compounds which modulate TNF production and compounds which act on biochemical pathways leading to TNF synthesis. Compositions include a combination of (i) and (ii) above, together with acceptable pharmaceutical carriers and/or vehicles.Type: ApplicationFiled: January 14, 2003Publication date: May 6, 2004Inventors: Bruce Charles Baguley, Lai-Ming Ching, Martin Philpott
-
Publication number: 20040086498Abstract: A method is provided for treating mammals, including humans, with advanced or large-tumour burdens. The method involves administering an immunotherapeautic agent in conjunction with a tumour growth restricting agent, in amounts effective to eradicate any advanced or large tumours present. In preferred embodiments, the immunotherapeautic agent comprises a T-cell co-stimulatory cell adhesion molecule (CAM) or a mammalian expression vector containing DNA which encodes a T-cell co-stimulatory CAM, such as B7.1, and the tumour growth restricting agent is flavone acetic acid, 5,6-dimenthyl-xanthenone-4-acetic acid, or an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).Type: ApplicationFiled: December 11, 2001Publication date: May 6, 2004Inventors: Geoffrey W. Krissansen, Jagat Rakesh Kanwar, Lai-Ming Ching
-
Publication number: 20040082648Abstract: This disclosure describes new antibiotic Cytosporacin having the structure: 1Type: ApplicationFiled: October 14, 2003Publication date: April 29, 2004Applicant: Wyeth Holdings CorporationInventors: Haiyin He, Jeffrey Edwin Janso